MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 406179 | Name: BS-181 HCl
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

BS-181 is a highly selective CDK inhibitor for CDK7 with an IC(50) of 21 nmol/L. Testing of other CDKs as well as another 69 kinases showed that BS-181 only inhibited CDK2 at concentrations lower than 1 micromol/L, with CDK2 being inhibited 35-fold less potently (IC(50) 880 nmol/L) than CDK7. In MCF-7 cells, BS-181 inhibited the phosphorylation of CDK7 substrates, promoted cell cycle arrest and apoptosis to inhibit the growth of cancer cell lines, and showed antitumor effects in vivo.

Chemical Structure

BS-181 HCl
BS-181 HCl
CAS#1883548-83-1 (2HCl)

Theoretical Analysis

MedKoo Cat#: 406179

Name: BS-181 HCl

CAS#: 1883548-83-1 (2HCl)

Chemical Formula: C22H34Cl2N6

Exact Mass: 0.0000

Molecular Weight: 453.46

Elemental Analysis: C, 58.27; H, 7.56; Cl, 15.64; N, 18.53

Price and Availability

Size Price Availability Quantity
10mg USD 90.00 Ready to ship
25mg USD 150.00 Ready to ship
50mg USD 250.00 Ready to ship
100mg USD 450.00 Ready to ship
200mg USD 850.00 Ready to ship
500mg USD 1,750.00 Ready to ship
1g USD 2,950.00 Ready to ship
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
1092443-52-1 (free base) 1883548-83-1 (2HCl) 1397219-81-6 (HCl)
Synonym
BS181; BS-181; BS 181; BS-181 HCl; BS-181 hydrochloride.
IUPAC/Chemical Name
N5-(6-aminohexyl)-N7-benzyl-3-isopropylpyrazolo[1,5-a]pyrimidine-5,7-diamine dihydrochloride
InChi Key
XYXAMTBYYTXHSO-UHFFFAOYSA-N
InChi Code
InChI=1S/C22H32N6.2ClH/c1-17(2)19-16-26-28-21(25-15-18-10-6-5-7-11-18)14-20(27-22(19)28)24-13-9-4-3-8-12-23;;/h5-7,10-11,14,16-17,25H,3-4,8-9,12-13,15,23H2,1-2H3,(H,24,27);2*1H
SMILES Code
CC(C1=C2N=C(NCCCCCCN)C=C(NCC3=CC=CC=C3)N2N=C1)C.[H]Cl.[H]Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>5 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
        
Biological target:
BS-181 dihydrochloride is a potent and selective CDK7 inhibitor (IC50=21 nM) with activity against CDK2, CDK5 and CDK9 with IC50 values of 880 nM, 3000 nM and 4200 nM, respectively.
In vitro activity:
Cell apoptosis was determined using flow cytometry. Significant increases in apoptotic cells were observed in BS-181-treated BGC823 cells compared to control (P<0.05, respectively; Figure 2A). Our results also showed that BS-181-induced cell apoptosis in a dose- and time-dependent manner. Additionally, caspase-3 and Bax expressions have been significantly increased, while Bcl-2 level has been reduced in cells treated with BS-181 compared to control (P<0.05, respectively) (Figure 2B). These results indicated that BS181 could induce apoptosis in GC cells. Furthermore, the inhibition of CDK7 activity led to a significant reduction of key antiapoptotic protein XIAP and cell cycle regulator cyclin D1 (P<0.05) (Figure 2C). Thus, BS-181 may regulate cell apoptosis and cell cycle progression via downregulating XIAP and cyclin expression in BGC823 cells. In the present study, cell cycle distribution was analyzed by flow cytometry (Figure 3). Treatment of BS-181 showed an increase in cells in G0/G1, accompanied by a reduction of cell population in S and G2/M phases. These results indicated that BS-181-induced cell cycle arrest in the G0/G1 phase and delayed the progression of the cell cycle Drug Des Devel Ther. 2016; 10: 1181–1189. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4801149/
In vivo activity:
In this study, mice received intraperitoneal injection of BS-181 twice daily with 5 mg/kg/d or 10 mg/kg/d to give daily doses of 10 mg/kg or 20 mg/kg, over a period of 2 weeks. In addition, another group of 15 rats received roscovitine (20 mg/kg/d) injection for a total of 14 days. We observed that tumor growth was significantly inhibited by BS-181 in a dose-dependent manner compared to the control group (P<0.05, respectively) (Figure 5A). However, there was no significant difference in mice body weights between groups during a 14-day observation (Figure 5B). This indicated that there was no apparent toxicity at a daily dose of 10 mg/kg or 20 mg/kg. In addition, all animals were kept for another 30 days for survival observation. As seen in Figure 5C, eight of ten mice (80%) died in the control group, five of ten (50%) died in the roscovitine group, while six of ten (60%, 10 mg/kg/d) and three of ten (30%, 20 mg/kg/d) mice died in BS-181-treated groups. The overall difference in survival rate between rats treated with or without BS-181 was significant (P<0.05, respectively). Therefore, BS-181 provides potent and selective CDK7 inhibitor with the potential as an antigastric cancer agent. Drug Des Devel Ther. 2016; 10: 1181–1189. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4801149/
Solvent mg/mL mM
Solubility
DMSO 45.3 100.00
H2O 45.3 100.00
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 453.46 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Wang BY, Liu QY, Cao J, Chen JW, Liu ZS. Selective CDK7 inhibition with BS-181 suppresses cell proliferation and induces cell cycle arrest and apoptosis in gastric cancer. Drug Des Devel Ther. 2016 Mar 16;10:1181-9. doi: 10.2147/DDDT.S86317. PMID: 27042010; PMCID: PMC4801149. 2. Park SY, Kim KY, Jun DY, Hwang SK, Kim YH. G1 Cell Cycle Arrest and Extrinsic Apoptotic Mechanisms Underlying the AntiLeukemic Activity of CDK7 Inhibitor BS-181. Cancers (Basel). 2020 Dec 19;12(12):3845. doi: 10.3390/cancers12123845. PMID: 33352782; PMCID: PMC7766600. 3.Ali S, Heathcote DA, Kroll SH, Jogalekar AS, Scheiper B, Patel H, Brackow J, Siwicka A, Fuchter MJ, Periyasamy M, Tolhurst RS, Kanneganti SK, Snyder JP, Liotta DC, Aboagye EO, Barrett AG, Coombes RC. The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity. Cancer Res. 2009 Aug 1;69(15):6208-15. doi: 10.1158/0008-5472.CAN-09-0301. Epub 2009 Jul 28. PMID: 19638587; PMCID: PMC2875168.
In vitro protocol:
1. Wang BY, Liu QY, Cao J, Chen JW, Liu ZS. Selective CDK7 inhibition with BS-181 suppresses cell proliferation and induces cell cycle arrest and apoptosis in gastric cancer. Drug Des Devel Ther. 2016 Mar 16;10:1181-9. doi: 10.2147/DDDT.S86317. PMID: 27042010; PMCID: PMC4801149. 2. Park SY, Kim KY, Jun DY, Hwang SK, Kim YH. G1 Cell Cycle Arrest and Extrinsic Apoptotic Mechanisms Underlying the AntiLeukemic Activity of CDK7 Inhibitor BS-181. Cancers (Basel). 2020 Dec 19;12(12):3845. doi: 10.3390/cancers12123845. PMID: 33352782; PMCID: PMC7766600.
In vivo protocol:
1. Wang BY, Liu QY, Cao J, Chen JW, Liu ZS. Selective CDK7 inhibition with BS-181 suppresses cell proliferation and induces cell cycle arrest and apoptosis in gastric cancer. Drug Des Devel Ther. 2016 Mar 16;10:1181-9. doi: 10.2147/DDDT.S86317. PMID: 27042010; PMCID: PMC4801149. 2. Ali S, Heathcote DA, Kroll SH, Jogalekar AS, Scheiper B, Patel H, Brackow J, Siwicka A, Fuchter MJ, Periyasamy M, Tolhurst RS, Kanneganti SK, Snyder JP, Liotta DC, Aboagye EO, Barrett AG, Coombes RC. The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity. Cancer Res. 2009 Aug 1;69(15):6208-15. doi: 10.1158/0008-5472.CAN-09-0301. Epub 2009 Jul 28. PMID: 19638587; PMCID: PMC2875168.
1: Ali S, Heathcote DA, Kroll SH, Jogalekar AS, Scheiper B, Patel H, Brackow J, Siwicka A, Fuchter MJ, Periyasamy M, Tolhurst RS, Kanneganti SK, Snyder JP, Liotta DC, Aboagye EO, Barrett AG, Coombes RC. The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity. Cancer Res. 2009 Aug 1;69(15):6208-15. doi: 10.1158/0008-5472.CAN-09-0301. Epub 2009 Jul 28. PubMed PMID: 19638587; PubMed Central PMCID: PMC2875168.